It’s a derisking moment. If the Azer-Cel trials were to fail we’ve already got our money back and we are off the hook.
If they are a big success, we’ve got our supply lines sorted. And the cost of goods will be insignificant once the drugs hit the market. Probably around $3-$400k patient for The first indication. Seriously big money.
Once the first 10 cohort in the confirmation trial is successful, this is ready to licence or sell off.
Ann: Imugene & Kincell Bio Strategic Partnership Investor Webinar, page-10
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.3¢ |
Change
-0.001(1.85%) |
Mkt cap ! $389.5M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.6¢ | 5.3¢ | $615.0K | 11.39M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 2977440 | 5.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.4¢ | 283236 | 4 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |